drug · small molecule
milvexian
Phase 3updated 6mo agoby Bristol-Myers Squibb Co🔗 ChEMBL
Phase 3community read0 votes
Small molecule drug with a maximum clinical stage of Phase 3 (across all indications), with 5 investigational indications.
indications
indications
Atrial Fibrillation
targets
Coagulation factor XI
all catalysts(0)
nothing on the calendar yet
Trials studying milvexian
- phase3A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
- phase3A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
- phase3A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome
- phase1A Study to Assess the Reversal of the Anticoagulant Effects of Milvexian by 4-Factor Prothrombin Complex Concentrate (4F-PCC) (Part 1) and Recombinant Human Factor VIIa (rFVIIa) (Part 2) in Healthy Participants
- phase1A Study of JNJ-70033093 (Milvexian) in Healthy Adult Participants
- phase1A Study of Milvexian in Healthy Adult Females
- phase1A Study Evaluating Drug Drug Interaction Between Milvexian and Atorvastatin in Healthy Participants
News(10)
- Deep dive: Cardiovascular calamities and catalystsBioSpace reviews upcoming cardiovascular milestones after a summer of missed targets.biospace · 4d ago
- BMS R&D head to depart amid restructureBristol Myers Squibb is combining all research and development efforts under one leader as pressure rises to replenish its pipeline.biospace · 4d ago
- Bayer wins first-in-class FDA nod for blood thinner, setting stage for BMS-J&J rivalBayer’s Sunharbo has secured the first FDA approval of its class, establishing a regulatory pathway for other factor XIa inhibitors, such as Bristol Myers Squibb and Johnson and Johnson’s milvexian.biospace · 6d ago
- Bayer wins FDA nod for a new kind of blood thinnerSunharbo’s U.S. approval is the first for a “Factor XIa” inhibitor, an anticipated class of medicines seen as a possible step forward in stroke prevention.biopharma_dive · 7d ago
- BMS drops Prothena-partnered neuro drug, sales outlook improves on a Q3 beatIn addition to canning an Orum-acquired blood cancer candidate last month, Bristol Myers Squibb cut a Prothena-partnered neuro asset in the third quarter. But with sales climbing 7%, the Big Pharma…biospace · 18d ago
- J&J earnings set ‘negative tone’; Shkreli vs. the FTCA 6% sell-off in J&J shares was viewed by one analyst as emblematic of broader market volatility. Elsewhere, Gilead is collaborating with Vir and a biotech’s bid for a product expansion fell short.biopharma_dive · 1mo ago
- BMS’ Phase 3 win for lung drug clouded by high-dose missA low-dose win could derisk a regulatory pathway for BMS’ LPA1 antagonist in idiopathic pulmonary fibrosis after a recently reported patient death, but a miss at the higher dose leaves analysts awa…biospace · 1mo ago
- BMS doubles up with pivotal wins in lung disease, solid tumor that offer hope for post-patent cliff growthBristol Myers Squibb has reported phase 3 wins in a lung disease and a solid tumor, taking two steps on its path toward post-patent cliff growth.fiercebiotech · 1mo ago
- BMO most bullish on Merck's, bearish on BMS’ plans to contend with patent cliffsBMO Capital Markets is more impressed by Merck’s plans to replace lost Keytruda revenue than on Bristol Myers Squibb’s efforts to fill the expected void that will come from loss of exclusivity for…biospace · 1mo ago
- BMS reports liver injury events in lung disease program, with key readout nearBristol Myers Squibb will soon release Phase 3 data for admilparant that could make or break Contineum Therapeutics’ rival product. But reports of a death due to liver injury in the pharma’s progra…biospace · 1mo ago
Data sources
last refreshed 5h ago
Found something off?
comments(0)
5-min edit window · permanent after that